BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state

BRD9通过调控染色质状态决定造血干细胞的细胞命运

阅读:4
作者:Muran Xiao # ,Shinji Kondo # ,Masaki Nomura # ,Shinichiro Kato ,Koutarou Nishimura ,Weijia Zang ,Yifan Zhang ,Tomohiro Akashi ,Aaron Viny ,Tsukasa Shigehiro ,Tomokatsu Ikawa ,Hiromi Yamazaki ,Miki Fukumoto ,Atsushi Tanaka ,Yasutaka Hayashi ,Yui Koike ,Yumi Aoyama ,Hiromi Ito ,Hiroyoshi Nishikawa ,Toshio Kitamura ,Akinori Kanai ,Akihiko Yokoyama ,Tohru Fujiwara ,Susumu Goyama ,Hideki Noguchi ,Stanley C Lee ,Atsushi Toyoda ,Kunihiko Hinohara ,Omar Abdel-Wahab ,Daichi Inoue

Abstract

ATP-dependent chromatin remodeling SWI/SNF complexes exist in three subcomplexes: canonical BAF (cBAF), polybromo BAF (PBAF), and a newly described non-canonical BAF (ncBAF). While cBAF and PBAF regulate fates of multiple cell types, roles for ncBAF in hematopoietic stem cells (HSCs) have not been investigated. Motivated by recent discovery of disrupted expression of BRD9, an essential component of ncBAF, in multiple cancers, including clonal hematopoietic disorders, we evaluate here the role of BRD9 in normal and malignant HSCs. BRD9 loss enhances chromatin accessibility, promoting myeloid lineage skewing while impairing B cell development. BRD9 significantly colocalizes with CTCF, whose chromatin recruitment is augmented by BRD9 loss, leading to altered chromatin state and expression of myeloid-related genes within intact topologically associating domains. These data uncover ncBAF as critical for cell fate specification in HSCs via three-dimensional regulation of gene expression and illuminate roles for ncBAF in normal and malignant hematopoiesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。